Skip to content
Companies

CND Life Sciences

Skin biopsy test for Parkinson's disease

Raised to date

$15M

of $15.3M offered across 3 Form D filings

Still open
$352K
Investors
27
Last filed
Aug 3, 2026

About

CND Life Sciences, Inc. is a pioneering medical technology company focused on developing diagnostic solutions for neurodegenerative diseases, particularly those related to abnormal protein accumulation in the nervous system. Their innovative approach centers around minimally invasive skin-based diagnostics aimed at improving the accuracy of diagnosing conditions like Parkinson’s disease and related disorders.

The company stands out for its Syn-One Test®, the first commercially available test that detects misfolded alpha-synuclein proteins using simple skin biopsies.

Funding

$9M round, first sold Feb 2025$8.6M sold$352K still openFeb 20252026
Now
  • DebtFiled Aug 3, 2026Form D/A
    $6.3M/ $6.3M
  • DebtFiled Jun 16, 2026Form D
    $4.3M/ $6.3M
  • EquityFiled May 6, 2025Form D/A
    $8.6M/ $9M

Product

Syn-One Test®

Diagnostic Testing

The Syn-One Test® is a groundbreaking, minimally invasive diagnostic tool that detects and quantifies the presence of misfolded, phosphorylated alpha-synuclein in skin nerve fibers. This test is processed in a CLIA-certified and CAP-accredited laboratory through a straightforward procedure that requires three small skin biopsy samples.

  • World's first commercially available skin-based diagnostic test
  • High sensitivity and specificity rates exceeding 95%
  • Utilizes proprietary immunofluorescence techniques and NerValence™ AI pathology

Built for

Neurologists and biopharmaceutical companies

People on file